



# HELP IMPROVE CLEANING EFFICACY

## CLOSTRIDIoidES DIFFICILE: AN INFECTIOUS BACTERIUM



INCREASES AVERAGE  
HOSPITAL STAY BY  
**4 DAYS**<sup>1\*</sup>



ASSOCIATED WITH  
**12,000-30,000**  
**DEATHS**  
ANNUALLY<sup>1\*\*</sup>



COSTS CDI MANAGEMENT  
UP TO  
**4.9 BILLION**  
ANNUALLY<sup>1\*\*\*</sup>

## WHAT YOU NEED TO KNOW

### WHAT IS *C. DIFF*?

*C. diff* (also known as *Clostridioides difficile* or *C. difficile*) is a very hearty bacteria that is capable of frequently contaminating the healthcare environment, including patient skin sites, hands of healthcare workers, and environmental surfaces.

### WHY IS IT A CONCERN?

In the US, *C. difficile* has been classified by the CDC as one of the most urgent antibiotic-resistant public health threats and one that requires 'urgent and aggressive action.' This classification is due to the profound morbidity, mortality, and excess healthcare expenditures associated with CDI (*Clostridioides difficile* infection). *C. diff* is estimated to cause almost half a million infections in the United States including >225,000 cases in hospitalized patients each year.<sup>1</sup>

### HOW DOES IT SPREAD?

*C. diff* is shed in feces. Any surface, device, or material that becomes contaminated with feces could serve as a reservoir for the *C. diff* spores. *C. diff* spores can also be transferred to patients via the hands of healthcare personnel who have touched a contaminated surface or item.

### WHO IS AT RISK?

*C. diff* can affect anyone. However, most cases occur when a patient has been taking antibiotics or not long after the patient has finished taking antibiotics. Patients that are 65 years old or older, are on medication to suppress gastric acid, or had a previous *C. diff* infection are at greater risk.



For more information on *C. diff*, you can visit:  
<https://www.cdc.gov/cdiff/index.html>

<sup>1</sup>Source: <https://doi.org/10.1017/ice.2023.18>    <sup>\*</sup>CDI increases hospital length of stay by 2.8-5.5 days    <sup>\*\*</sup>CDI is associated with 12,000-30,000 US deaths each year

<sup>\*\*\*</sup>US hospital costs for CDI management are estimated at \$1.0 billion-\$4.9 billion per year.




# HELP IMPROVE CLEANING EFFICACY

REMOVES  
**99.7%**  
OR MORE OF *C. DIFF*  
AND OTHER TESTED  
PATHOGENS\*


## HYGEN™ DURABLE MICROFIBER

ITEM #	DESCRIPTION	CASE PACK
FGQ62000RD00	HYGEN™ 16" X 16" MICROFIBER CLOTH, RED	12
FGQ62006GR00	HYGEN™ 16" X 16" MICROFIBER CLOTH, GREEN	6
FGQ62000GR00	HYGEN™ 16" X 16" MICROFIBER CLOTH, GREEN	12
FGQ62000BL00	HYGEN™ 16" X 16" MICROFIBER CLOTH, BLUE	12
FGQ61000YL00	HYGEN™ 16" X 16" MICROFIBER CLOTH, YELLOW	12
FGQ41000RD00	HYGEN™ 18" MICROFIBER WET PAD, RED	12
FGQ41000GR00	HYGEN™ 18" MICROFIBER WET PAD, GREEN	12
FGQ41000BL00	HYGEN™ 18" MICROFIBER WET PAD, BLUE	12




## HYGEN™ DISPOSABLE MICROFIBER

ITEM #	DESCRIPTION	CASE PACK
2134283	HYGEN™ 12" X 12" DISPOSABLE MICROFIBER CLOTH	600
2134282	HYGEN™ 18" DISPOSABLE MICROFIBER PAD	150
2135007	HYGEN™ DISPOSABLE MICROFIBER CHARGING TUB	4



## LIGHT COMMERCIAL MICROFIBER

ITEM #	DESCRIPTION	CASE PACK
1820577	12" X 12" LIGHT COMMERCIAL MICROFIBER CLOTH, RED	288
1820578	12" X 12" LIGHT COMMERCIAL MICROFIBER CLOTH, GREEN	288
1820579	12" X 12" LIGHT COMMERCIAL MICROFIBER CLOTH, BLUE	288
1820580	12" X 12" LIGHT COMMERCIAL MICROFIBER CLOTH, YELLOW	288
1820581	16" X 16" LIGHT COMMERCIAL MICROFIBER CLOTH, RED	288
1820582	16" X 16" LIGHT COMMERCIAL MICROFIBER CLOTH, GREEN	288
1820583	16" X 16" LIGHT COMMERCIAL MICROFIBER CLOTH, BLUE	288
1820584	16" X 16" LIGHT COMMERCIAL MICROFIBER CLOTH, YELLOW	288



\*Tested pathogens: Methicillin-resistant Staphylococcus aureus (MRSA), Clostridioides difficile (C. diff), Pseudomonas Aeruginosa (Pseudo), Common human coronavirus OC43, SARS-CoV-2, Omicron Variant†, Feline Calicivirus (surrogate for norovirus), Candida auris (C. auris) †Lineage B.1.1.529, BEI Resources #NR-56461 EPA Est Nos. 91158-IND-1, 91635-VNM-001, 92100-CHN-1